STERIS Announces Dividend of $0.63 per share

Rhea-AI Summary

STERIS (NYSE: STE) announced a quarterly cash dividend of $0.63 per share, payable on December 18, 2025 to shareholders of record as of November 18, 2025. The company noted U.S. tax-treatment information and Forms 8937 are available on its investor website.

The release reiterates forward-looking cautionary language about risks that could affect future results, including operating costs, integration of acquisitions, litigation, and macroeconomic factors.

Positive

• $0.63 quarterly dividend declared
• Dividend payable on Dec 18, 2025 to record holders at Nov 18, 2025

Negative

• Quarterly dividend triggers a near-term cash outflow on Dec 18, 2025
• Forward-looking risks cited include litigation and integration risks that could affect results

DUBLIN, IRELAND, Oct. 29, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on December 18, 2025, to shareholders of record at the close of business on November 18, 2025.  

Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com.

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe.

Company Contact:

Julie Winter, Vice President, Investor Relations and Corporate Communications

Julie_Winter@steris.com

440.392.7245

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology.

Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those identified in STERIS’s recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins; (b) STERIS’s ability to successfully integrate acquired businesses into its existing businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of such businesses; (c) changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, or tariffs and/or other trade barriers; (d) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the Isomedix litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS’s performance, results, prospects or value; (e) the potential of international unrest, including military conflicts, economic downturn and effects of currency fluctuations; (f) the possibility of delays in receipt of orders, order cancellations, or the manufacture or shipment of ordered products; (g) the possibility that anticipated growth, performance or other results may not be achieved, or that timing, execution, impairments, or other issues associated with STERIS’s businesses, industry or initiatives may adversely impact STERIS’s performance, results, prospects or value; (h) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments; (i) the possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than anticipated; (j) the level of STERIS’s indebtedness limiting financial flexibility or increasing future borrowing costs; (k) the effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS’s Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed; (l) the impacts of increasing competition within our industry, which may exert pressure on our pricing strategy or lead to decreasing demand for our products and services; (m) the effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions; (n) the possibility of economic downturns and recessions, which could negatively impact our business by reducing consumer and Customer spending. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.

FAQ

What dividend did STERIS (STE) announce on October 29, 2025?

STERIS announced a quarterly cash dividend of $0.63 per share on October 29, 2025.

When is the STERIS (STE) dividend payable and what is the record date?

The dividend is payable on December 18, 2025 to shareholders of record at the close of business on November 18, 2025.

How can STERIS shareholders find U.S. tax information for the dividend (STE)?

U.S. tax treatment details and required Forms 8937 are available on STERIS's investor relations website.

Will STERIS (STE) update forward-looking guidance with this dividend announcement?

The announcement does not provide new guidance; it reiterates general forward-looking cautionary language without updated forecasts.

Does the STERIS (STE) dividend announcement mention litigation risk affecting shareholders?

Yes; the release lists litigation, including the Isomedix litigation, among risks that could affect results.

What should investors note about the cash impact of STERIS's (STE) December 2025 dividend?

Investors should note the dividend creates a scheduled cash outflow on December 18, 2025 payable to record holders on November 18, 2025.